FAIRFIELD, N.J.--(BUSINESS WIRE)--Aug. 3, 2007--Unigene
Laboratories, Inc. (OTCBB: UGNE) will deliver a presentation at the
27th Annual Canaccord Adams Global Growth Conference in Boston, one of
the longest-running institutional events focused exclusively on growth
companies. Dr. Warren Levy, President and CEO, is scheduled to present
to leading institutional investment representatives on Tuesday, August
7, 2007, at the InterContinental Boston.
"Long known as the Summer Seminar, this year we have changed the
name of the event to better reflect the expanding international scope
of companies and investors attending," said Kevin Dunn, President and
CEO of Canaccord Adams Inc. "It is our continued mission to deliver a
top quality event for institutional clients and venture capitalists,
connecting them with exciting growth companies. The conference will
also afford corporate clients access to investing insights and
valuable market information. Our goal is to provide a premier forum
for sharing knowledge, discussing emerging trends and identifying
investment opportunities for public and private companies, venture
capitalists and institutional investors."
About Unigene Laboratories, Inc.:
Unigene Laboratories, Inc. is a biopharmaceutical company focusing
on the oral and nasal delivery of large-market peptide drugs. Due to
the size of the worldwide osteoporosis market, Unigene is targeting
its initial efforts on developing calcitonin and PTH-based therapies.
Fortical(R), Unigene's nasal calcitonin product for the treatment of
postmenopausal osteoporosis, received FDA approval and was launched in
August 2005. Unigene has licensed the U.S. rights for Fortical(R) to
Upsher-Smith Laboratories, worldwide rights for its oral PTH
technology to GlaxoSmithKline and worldwide rights for its calcitonin
manufacturing technology to Novartis. Unigene's patented oral delivery
technology has successfully delivered, in preclinical and/or clinical
trials, various peptides including calcitonin, PTH and insulin.
Unigene's patented manufacturing technology is designed to
cost-effectively produce peptides in quantities sufficient to support
their worldwide commercialization as oral or nasal therapeutics. For
more information about Unigene, call (973) 882-0860 or visit
www.unigene.com. For information about Fortical, visit
www.fortical.com.
About Canaccord Adams' Global Growth Conference:
The Canaccord Adams Global Growth Conference is one of the oldest
and largest programs showcasing both publicly traded and privately
held growth companies. Many of the presenting public companies are
covered by Canaccord Adams' global team of equity analysts. To learn
more about the conference, please contact Nadine Miller at
617.371.3842 or Nadine.Miller@CanaccordAdams.com.
About Canaccord Adams:
Canaccord Adams is a leading independent financial services firm
committed to fostering the entrepreneurial economy by bringing
corporate and institutional clients a unique perspective on global
investment opportunities. With operations in research, sales and
trading, and investment banking, our 225 professionals seek out
emerging opportunities in our key sectors -- Mining and Metals,
Energy, Technology, Life Sciences, Real Estate, and Industrial Growth.
Located in ten offices internationally, our experienced team generates
focused, actionable ideas that identify opportunity and facilitate
growth. Canaccord Adams, the international capital markets division of
Canaccord Capital Inc., has operations in Toronto, London, Boston,
Vancouver, New York, Calgary, Montreal, San Francisco, Houston and
Chicago. More information is available at www.canaccordadams.com.
Canaccord Adams Inc., Member NASD/SIPC. Canaccord Adams Limited is
regulated and authorized by the Financial Services Authority and is a
member of the LSE. Canaccord Adams is a division of Canaccord Capital
Corporation, Member IDA/CIPF.
About Canaccord Capital Inc.:
Through its principal subsidiaries, Canaccord Capital Inc. (TSX &
AIM: CCI) is a leading independent full-service investment dealer in
Canada, with capital markets operations in the United Kingdom and the
United States of America. Canaccord is publicly traded on both the
Toronto Stock Exchange and AIM, a market operated by the London Stock
Exchange. Canaccord has operations in two of the principal segments of
the securities industry: private client services and capital markets.
Together these operations offer a wide range of complementary
investment products, brokerage services and investment banking
services to Canaccord's private, institutional and corporate clients.
Canaccord has approximately 1,570 employees worldwide in 31 offices,
including 23 Private Client Services offices located across Canada.
Canaccord Adams, the international capital markets division, has
operations in Toronto, London, Boston, Vancouver, New York, Calgary,
Montreal, San Francisco, Houston and Chicago.
Safe Harbor statements under the Private Securities Litigation
Reform Act of 1995: This press release contains forward-looking
statements as defined in Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Such forward-looking statements are based upon Unigene
Laboratories, Inc.'s management's current expectations, estimates,
beliefs, assumptions, and projections about Unigene's business and
industry. Words such as "anticipates," "expects," "intends," "plans,"
"predicts," "believes," "seeks," "estimates," "may," "will," "should,"
"would," "potential," "continue," and variations of these words (or
negatives of these words) or similar expressions, are intended to
identify forward-looking statements. In addition, any statements that
refer to expectations, projections, or other characterizations of
future events or circumstances, including any underlying assumptions,
are forward-looking statements. These forward-looking statements are
not guarantees of future performance and are subject to certain risks,
uncertainties, and assumptions that are difficult to predict.
Therefore, our actual results could differ materially and adversely
from those expressed in any forward-looking statements as a result of
various risk factors. These risks and uncertainties include the risks
associated with the effect of changing economic conditions, trends in
the products markets, variations in Unigene's cash flow, market
acceptance risks, technical development risks and other risk factors
detailed in Unigene's Securities and Exchange Commission filings.
CONTACT: Unigene Investors:
The Investor Relations Group
Daniel Berg/Dian Griesel, Ph.D., 212-825-3210
Or
Media:
Lynn Granito, 212-825-3210
SOURCE: Unigene Laboratories, Inc.
|
